Eli Lilly’s M&A Friday; Novartis' TIGIT breakup; One big hire and one big exit; Reverse merger, shutdown and white flags; and more
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.
We’re just a few days away from unveiling this year’s list of women blazing trials in biopharma R&D. In addition to an award ceremony in which you will get to hear snippets from our interview with honorees. I will be hosting Fiona Marshall, president of the Novartis Institutes for BioMedical Research, for a fireside chat, while my colleague Nicole DeFeudis will moderate a panel with a trio of women leaders who are making their voices heard. We hope to see you there.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.